Pluristem (PSTI +2.5%) says the FDA has acknowledged that aplastic anemia is a rare disease,...

|About: Pluristem Therapeutics, Inc. (PSTI)|By:, SA News Editor

Pluristem (PSTI +2.5%) says the FDA has acknowledged that aplastic anemia is a rare disease, confirming that potential treatments for the condition are eligible for orphan drug status. However, it also has requested that PSTI provide additional information and data for further analysis before the agency can determine if PLX cells can qualify for orphan drug designation for aplastic anemia. PSTI is focusing on the use of the cells to treat systemic diseases eliminate the need to use the intravenous route.